ProCE Banner Activity

My Thoughts on the Potential of AKT Inhibitors in Metastatic Breast Cancer

Clinical Thought

Expert faculty discuss the potential role of investigational AKT inhibitors in metastatic breast cancer.

Released: August 15, 2023

Share

Faculty

Joyce O'Shaughnessy

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Faculty Disclosure

Primary Author

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Dallas, Texas

Joyce O'Shaughnessy, MD: consultant/advisor: AbbVie Inc., Agendia, Aptitude Health, AstraZeneca, Bayer, Bristol-Myers Squibb, Caris, Carrick Therapeutics, Celgene Corporation, Daiichi Sankyo, Eisai, Exact Sciences, Fishawack Health, G1 Therapeutics, GlaxoSmithKline, Genentech, Gilead Sciences, Immunomedics, Incyte Corporation, Lilly, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Prime Oncology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Theralink, Synthon, Veru.